Kimia Farma (Persero) Tbk PT operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kimia Farma (Persero) Tbk PT with three other
pharmaceutical manufacturers in Asia:
Shenzhen Hepalink Pharmaceutical Company Limited
sales of 1.96 billion Chinese Renmimbi [US$307.90 million]
of which 100%
was Pharmaceutical Manufacturing),
ChangChun High New Technology Industries
(2.23 billion Chinese Renmimbi [US$351.46 million]
of which 79%
was Medication), and
Yabao Pharmaceutical Group Company Limited
based in China
(1.89 billion Chinese Renmimbi [US$297.25 million]
of which 85%
was Pharrmaceutical Manufacturing).
Kimia Farma (Persero) Tbk PT reported sales of 4.52 trillion Indonesian Rupiahs (US$311.95 million)
December of 2014.
increase of 4.0%
versus 2013, when the company's sales were 4.35 trillion Indonesian Rupiahs.
Sales at Kimia Farma (Persero) Tbk PT have increased during each of the previous five years
(and since 2009, sales have increased a total of 58%).
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
33.7% in 2014, from
49.16 billion Indonesian Rupiahs to 65.72 billion Indonesian Rupiahs.
Kimia Farma (Persero) Tbk PT also saw significant increases in sales in
Retail (up 10.0% to 2.43 trillion Indonesian Rupiahs)
Manufacturing (up 27.5% to 195.86 billion Indonesian Rupiahs)
Not all segments of Kimia Farma (Persero) Tbk PT experienced an increase in sales in 2014:
sales of Distribution fell 5.6% to 1.83 trillion Indonesian Rupiahs.